Sermorelin

Sermorelin is the molecular grandfather of the GHRH-analog peptide family. It was synthesized in the early 1980s as the minimum-active fragment of the GHRH peptide isolated at Salk in 1982, and reached the US market under the Serono brand Geref in two regulatory steps. The diagnostic formulation (Geref Diagnostic, 0.05 mg/amp, NDA 19-863) was approved in December 1990 as a provocative test of pituitary somatotroph function in the workup of GH deficiency. The therapeutic formulations (0.5 mg/vial and 1.0 mg/vial, NDA 20-443) followed in 1997 for the treatment of idiopathic growth-hormone deficiency in pediatric patients with growth failure. EMD Serono notified the FDA in December 2008 that it was discontinuing both NDAs; the agency announced the withdrawal in the Federal Register of May 19, 2009, effective June 18, 2009. A 2013 Federal Register determination (Federal Register, 78 FR 14116, March 4, 2013) made the point explicit: Geref was not withdrawn for reasons of safety or effectiveness. The exit was commercial. That determination is what now anchors sermorelin's legal availability through 503A compounding pharmacies under the "component of an FDA-approved drug product" pathway.

The published trial base for sermorelin sits primarily in pediatric GH deficiency, not in adult anti-aging or recomposition use. The pediatric clinical case rests on small open-label and observational studies — Grunt et al., Acta Paediatrica 1995, 84:631-633 treated seven children with idiopathic short stature with subcutaneous sermorelin 30 µg/kg daily and reported that a subset demonstrated sustained height-velocity improvement over 24 months — together with the body of NDA-supporting work that underlay the 1997 Geref approval for pediatric idiopathic GH deficiency. The 1999 Prakash and Goa, BioDrugs 1999, 12:139-157 review summarizes the diagnostic and therapeutic pediatric trial base as it stood at the end of the 1990s: sermorelin at 1 µg/kg IV gave a relatively specific provocative test for GH deficiency with fewer false positives than other agents, and 30 µg/kg subcutaneous at bedtime drove catch-up growth in a portion of prepubertal children with idiopathic GH deficiency. The pediatric file is what earned the FDA approval; the indications it earned were narrow and the trial sizes were small.

The adult evidence base is thinner and structured around two questions that the regulatory file was not designed to answer. The first is whether nightly sermorelin restores age-attenuated GH/IGF-1 levels in healthy older adults; the second is what biological or functional outcomes such restoration produces. Khorram, Laughlin, and Yen, J Clin Endocrinol Metab 1997, 82:1472-1479 randomized 19 healthy adults aged 55-71 (n=10 women, n=9 men) to nightly subcutaneous [Nle27]GHRH(1-29)-NH₂ at 10 µg/kg or placebo in a 5-month single-blind crossover, and reported significantly increased nocturnal GH release, IGF-1 and IGFBP-3 elevation within two weeks, and lean-body-mass gain in men — a study small enough that it should be read as a mechanism and biomarker confirmation rather than a definitive effectiveness trial. Vittone et al., Metabolism 1997, 46:89-96 gave 11 healthy older men aged 64-76 a single nightly subcutaneous GHRH(1-29) dose of 2 mg for six weeks; nocturnal GH release rose and some isolated muscle-strength measures improved, but body weight, DEXA-measured body composition, glucose, insulin, and lipids did not change — and the authors specifically concluded that single nightly doses were less effective than multiple-daily-dose regimens at producing GH/IGF-1-mediated effects. Treat the Khorram and Vittone results as the load-bearing controlled adult evidence: GH and IGF-1 elevations are real and biomarker-confirmed; the body-composition and functional translation in non-deficient older adults is modest at best, and the trials that would settle the question in the modern compounding-pharmacy population have not been done.

The biohacker case for sermorelin sits downstream of that gap. The Walker 2006 editorial in Clinical Interventions in Aging is the most-cited articulation of the practitioner argument: that the off-label use of sermorelin is not legally prohibited in the way that off-label rhGH is, that the pulsatile, feedback-preserving GH stimulation it produces is mechanistically more defensible than exogenous rhGH for age-related GH decline, and that the molecule deserves serious clinical evaluation in adult-onset GH insufficiency. It is an editorial, not a trial — and it makes mechanism arguments, not outcome claims. Read the contemporary practitioner conversation around sermorelin through that lens: the legal-access argument is real, the pulsatile-mechanism argument is real, and the controlled outcome data in the indication that drives most current prescribing — adult body composition, recovery, sleep quality, and longevity-targeted use — does not yet exist. The GH-secretagogue discontinuation playbook covers the cycling logic that practitioner protocols overlay on this evidence base, and the /critic/sermorelin-naturalistic-fallacy response addresses the common framing that sermorelin's closer-to-endogenous sequence is intrinsically safer than the engineered analogs.

The honest framing has three parts. First, the published RCT-grade evidence sits in pediatric idiopathic GH deficiency, where the indication earned an FDA approval that the manufacturer voluntarily discontinued for commercial reasons. Second, the adult evidence base is small, mostly from the 1990s, and consistently shows that GH and IGF-1 biomarkers respond as the mechanism predicts — with translation to hard body-composition or functional endpoints in healthy older adults modest and route- and schedule-dependent. Third, the modern 503A-compounded use case for adult recomposition, sleep quality, and recovery is mechanistically plausible from the GHRH-axis literature and class-extrapolation from tesamorelin and CJC-1295, but is not what the Geref file was approved to test, and the controlled trials that would settle the question in that population have not been conducted. Sermorelin is the most-prescribed and most-studied GHRH-axis peptide in 2026 US clinical practice, and simultaneously the one whose marketed use case is furthest from its trial-grade evidence base.